Setsi sa Bongaka sa Univesithi ea Hackensack se thehile lenaneo le lecha la ho lebela batho ba kotsing e kholo ea ho tšoaroa ke mofetše oa manyeme.
Teko ea IMMray® PanCan-d ke teko ea pele ea mali 'marakeng e etselitsoeng tlhahlobo ea pele ea lefu la pancreatic ductal adenocarcinoma (PDAC).
Bakuli ba tšoanelehang ba tla fumana tlhahlobo ea litšoantšo le tlhahlobo e ncha ea biomarker e lekanyang karabelo ea sesole sa 'mele ho lefu la pancreatic maling.
Rosario Ligresti, MD, hlooho ea Gastroenterology Setsing sa Bongaka sa Hackensack, Setsi sa Sechaba sa Pancreas Foundation of Excellence ho tloha 2013, o re: "Mofets'e oa pejana o fumana monyetla o motle oa ho fumana kalafo e atlehileng." lenaneo la sepetlele la ho beha leihlo kotsing e kholo bakeng sa mofetše oa manyeme.
Ka bomalimabe, liphuputso li bontša hoo e ka bang kotara feela ea batho ba tšoanelehang bakeng sa ho beha leihlo kotsing e kholo ba hlile ba e sebelisa, empa Dr. Ligresti o lumela hore tlhahlobo ena e ncha ea mali e tla fetola papali.
Dr. Ligresti oa hlalosa: "Kankere ea manyeme, e leng e 'ngoe ea tse bolaeang ka ho fetisisa tsa mofets'e, ho thata ho lemoha kapele, nakong eo ka eona ho buuoang, e leng eona feela phekolo ea phekolo, e ka khonehang." "Teko ena e ncha e bonts'itsoe ho bona mofets'e oa pele oa pancreatic ho bakuli ba kotsing e kholo, ka sepheo sa ho e tšoara pele e ka ba le monyetla oa ho hasana le liseleng tse ling."
Ke mang ea nkoang a le kotsing e kholo?
Kankere ea manyeme e ka hlaha ka lapeng mme/kapa ea amahanngoa le maemo a lefutso a eketsang kotsi ea mefuta e meng ea mofetše. Sena se bitsoa mofetše oa pancreatic oa malapa 'me o kenyelletsa liketsahalo ho banab'eno, batsoali le ntate-moholo ho tloha melokong ea hajoale ea lelapa la hau. Uena le ba lelapa la hau le ka ba kotsing e kholo haeba beng ka uena ba 2 kapa ho feta ba boemo ba pele kapa bonyane litho tse 3 tsa lelapa li fumanoe li na le mofetše oa manyeme.
Tekanyetso ea hajoale ea tlhokomelo ea tlhahlobo ke efe?
Hajoale, tlhahlobo ea manyeme bakeng sa mofetše e etsoa ho sebelisoa MRI kapa endoscopic ultrasound (EUS). Ena ke tlhahlobo e khethehileng e kenyelletsang endoscope le high-frequency ultrasound ho etsa setšoantšo sa manyeme ka nepo. Liteko li etsoa selemo le selemo 'me ka bobeli li na le melemo le mathata. MRI e ka ba e boima, e theko e boima ebile e ja nako. EUS e kenyelletsa endoscopy e sa hlaseleng hanyane 'me e hloka ho itima lijo le ho khutsisa. Setsi sa Bongaka sa Univesithi ea Hackensack esale se etsa tlhahlobo ea manyeme ka mokhoa ona ka lilemo tse ngata. Pele ho mona, ha ho na tlhahlobo ea mali e khethehileng kapa e nepahetseng e fumanehang khoebong ho lumella tlhahlobo ea mofetše oa manyeme.
Ke mang ea tšoanelehang bakeng sa tlhahlobo ee e ncha ea mofetše oa manyeme?
Tlhahlobo ea mofetše oa manyeme e bohlokoa haholo lihlopheng tse latelang tse kotsing e kholo. Mokuli ofe kapa ofe ea fetang lilemo tse 18 ea nang le:
• Phetoho ea BRCA
• Cystic Fibrosis
• Familial Adenomatous Polyposis (FAP)
• Familial Atypical Multiple Mole Melanoma (FAMMM)
• Hereditary Nonpolyposis Colorectal Cancer (HNPCC) kapa Lynch Syndrome
• Pancreatitis ea Lefa
• phetoho ea PALB2
• Peutz-Jeghers Syndrome
• Histori ea lelapa ea mofets'e oa manyeme ho beng ka bona ba boemo ba pele
Protocol ea screening ke eng?
Bakuli ba tla ba le lipuisano tse felletseng le Dr. Ligresti. Joale ba tla ba le tlhahlobo ea IMMray PanCan-d hammoho le MRI kapa EUS e etsoang. Hang ha liphetho tsohle li fumaneha, ba tla kopana le Dr. Ligresti ho li hlahloba le moralo oa ho tsoela pele ho beha leihlo. Hangata sena se etsoa selemo le selemo.
Hobaneng ho le bohlokoa ho lemoha mofetše oa pancreatic pele ho nako? Matšoao a hlaha feela ka lefu la morao-rao, kahoo boholo ba mofetše oa pancreatic o fumanoa ka mor'a nako ha kalafo e sa sebetse hantle.
Ke mang ea kotsing ea ho tšoaroa ke mofetše oa manyeme? Ho tseba bakuli ba kotsing ea ho tšoaroa ke lefu lena ka lebaka la liphetoho tse tsebahalang tsa lefutso kapa nalane ea lelapa ea mofets'e oa pancreatic e ka ba ntho ea bohlokoa bakeng sa ho e fumana kapele. Lihlotšoana tse kotsing e kholo li emela karolo e kholo ea linyeoe tsohle tsa mofetše oa manyeme.
Teko ee e ncha e sebetsa joang? IMMray PanCan-d e sekaseka li-biomarker tse 9 ho serum ho bona pancreatic ductal adenocarcinoma (PDAC), mofuta o atileng haholo oa mofets'e oa manye. Li-biomarker tse amehang lits'ebetsong tse ngata tsa cellular tse kenyelletsang metabolism, ho ruruha le tšenyo ea lisele / tokiso, hammoho le CA19-9, li kenyelelitsoe tekong. Karabo ea sampole ho biomarker e 'ngoe le e 'ngoe ea lekanngoa ebe e kopanngoa ho sebelisoa algorithm ho fumana sephetho sa tlhahlobo ea "High-Risk Signature Present", "Negative for High-Risk Signature", kapa "Borderline".
Mosebetsi oa Teko: Khatisong ea morao-rao e hlahlobiloeng ke lithaka ea Brand et al e phatlalalitsoeng ho Clinical and Translational Gastroenterology, tlhahlobo ea IMMray PanCan-d e bontšitse kutlo ea 92% le makhethe a 99% ho lemoha pancreatic ductal adenocarcinoma (PDAC) ho sebelisoa serum. Teko ea IMMray PanCan-d e khonne ho lemoha Stage I & II PDAC e nang le kutlo ea 89% le 99% e ikhethang.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- In a recent peer-reviewed publication by Brand et al published in Clinical and Translational Gastroenterology, the IMMray PanCan-d test demonstrated a sensitivity of 92% and a specificity of 99% in….
- You and your family may be at an increased risk if 2 or more first-degree relatives or at least 3 members of the family have been diagnosed with pancreatic cancer.
- A sample’s response to each biomarker is measured and then combined using an algorithm to determine a test result of “High-Risk Signature Present”, “Negative for High-Risk Signature”, or “Borderline”.
